These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36809706)

  • 21. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
    Burnouf C; Pruniaux MP
    Curr Pharm Des; 2002; 8(14):1255-96. PubMed ID: 12052219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the therapeutic potential of PDE4 inhibitors.
    Dyke HJ; Montana JG
    Expert Opin Investig Drugs; 2002 Jan; 11(1):1-13. PubMed ID: 11772317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
    Michalski JM; Golden G; Ikari J; Rennard SI
    Clin Pharmacol Ther; 2012 Jan; 91(1):134-42. PubMed ID: 22130119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
    Crocetti L; Floresta G; Cilibrizzi A; Giovannoni MP
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
    Song Z; Huang YY; Hou KQ; Liu L; Zhou F; Huang Y; Wan G; Luo HB; Xiong XF
    J Med Chem; 2022 Mar; 65(5):4238-4254. PubMed ID: 35188767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
    Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
    Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase-4 inhibitor therapy for lung diseases.
    Beghè B; Rabe KF; Fabbri LM
    Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
    Barnette MS
    Prog Drug Res; 1999; 53():193-229. PubMed ID: 10616299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
    Jin SL; Ding SL; Lin SC
    Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
    Wittmann M; Helliwell PS
    Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
    Shan WJ; Huang L; Zhou Q; Jiang HL; Luo ZH; Lai KF; Li XS
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1523-6. PubMed ID: 22297114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential of PDE4 inhibitors in asthma or COPD.
    Spina D
    Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
    Banner KH; Press NJ
    Br J Pharmacol; 2009 Jul; 157(6):892-906. PubMed ID: 19508401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
    J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
    Wu C; Rajagopalan S
    Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.
    Lagente V; Martin-Chouly C; Boichot E; Martins MA; Silva PM
    Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():131-6. PubMed ID: 15962112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
    Smith VB; Spina D
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.